(S)-tert-butyl 1-methylpyrrolidin-3-ylcarbamate | 852874-60-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-tert-butyl 1-methylpyrrolidin-3-ylcarbamate
• 英文别名: (S)-tert-Butyl (1-methylpyrrolidin-3-yl)carbamate；tert-butyl N-[(3S)-1-methylpyrrolidin-3-yl]carbamate
• CAS: 852874-60-3
• 化学式: C₁₀H₂₀N₂O₂
• 分子量: 200.281
• InChiKey: ZAAYKTCDODPVPD-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 1-methylpyrrolidin-3-ylcarbamate 在 盐酸 、 甲醇 作用下， 以 水 为溶剂， 反应 16.0h， 生成 (S)-1-甲基吡咯烷-3-胺盐酸盐
  参考文献：
  名称：

  天然氨基酸衍生的双官能硫脲催化α-硝基环己酮与芳基硝基烯烃的不对称迈克尔加成反应

  摘要：

  由天然氨基酸制备的一系列新的硫脲催化剂已经用于α-硝基环己酮向硝基烯烃的有机催化不对称迈克尔加成中。形成的加成产物具有良好的对映选择性（高达98：2的er）和良好的产率（高达90％）。

  DOI：

  10.1021/ol302005f
• 作为产物：
  描述：

  BOC-L-天冬氨酸二甲酯 在 sodium tetrahydroborate 、 三乙胺 、 calcium chloride 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 22.0h， 生成 (S)-tert-butyl 1-methylpyrrolidin-3-ylcarbamate
  参考文献：
  名称：

  天然氨基酸衍生的双官能硫脲催化α-硝基环己酮与芳基硝基烯烃的不对称迈克尔加成反应

  摘要：

  由天然氨基酸制备的一系列新的硫脲催化剂已经用于α-硝基环己酮向硝基烯烃的有机催化不对称迈克尔加成中。形成的加成产物具有良好的对映选择性（高达98：2的er）和良好的产率（高达90％）。

  DOI：

  10.1021/ol302005f

文献信息

• Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist
  申请人：Huang Zhenhua

  公开号：US20130289029A1

  公开（公告）日：2013-10-31

  The present invention belongs to the technical field of medicine, relating in particular to: a fused ring compound as represented by Formula (I) for use as a mineralocorticoid receptor antagonist, a pharmaceutically acceptable salt thereof, and an isomer thereof; a preparation method for these compounds; a pharmaceutical preparation containing these compounds; and an application of these compounds, the pharmaceutically acceptable salt thereof, or the isomers thereof in the preparation of medicants for the treatment and/or prevention of kidney injury, cardiovascular diseases such as hypertension, and/or endocrine disease. The definitions of X, Y 1 , Y 2 , Y 3 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4 , Cy and n are as presented in the description.

  本发明属于医学技术领域，具体涉及以下内容：一种由化学式（I）表示的融合环化合物，用作醛固酮受体拮抗剂，其药学上可接受的盐和异构体；这些化合物的制备方法；含有这些化合物的药物制剂；以及这些化合物、其药学上可接受的盐或其异构体在制备用于治疗和/或预防肾损伤、高血压等心血管疾病和/或内分泌疾病的药物时的应用。X、Y1、Y2、Y3、R1、R2a、R2b、R3a、R3b、R4、Cy和n的定义如描述中所示。
• ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES
  申请人：Herman Jean

  公开号：US20140088088A1

  公开（公告）日：2014-03-27

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加合物盐和/或其立体异构体和/或其溶剂化合物，式(I)、(II)、(III)和(IV)中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，以及使用所述化合物来治疗或预防增殖性疾病以及用于制造治疗或预防增殖性疾病的药物，特别是像白血病这样的癌症。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防增殖性疾病。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗增殖性疾病和病理状况的药物，例如癌症如白血病等。
• THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS
  申请人：Herdewijn Piet

  公开号：US20120046278A1

  公开（公告）日：2012-02-23

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.

  本发明涉及式I、II、III或IV的化合物，及/或其药用可接受的加合盐和/或其立体异构体和/或其溶剂化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求1所定义。本发明还涉及它们的制备方法，以及其药物组合物。本发明进一步涉及所述化合物作为生物活性成分的用途，更具体地作为治疗疾病和病理状况的药物，例如但不限于免疫和自身免疫性疾病、器官和细胞移植排斥反应。
• Antiviral Activity of Novel Bicyclic Heterocycles
  申请人：De Jonghe Steven

  公开号：US20130190297A1

  公开（公告）日：2013-07-25

  The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加盐物和/或其立体异构体和/或其溶剂合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，并且涉及使用这些化合物来治疗或预防病毒感染以及用于制造用于治疗或预防病毒感染的药物，特别是属于逆转录病毒科、黄病毒科和小核病毒科家族的RNA病毒感染，更具体地是与人类免疫缺陷病毒1（HIV1）、人类免疫缺陷病毒2（HIV2）、丙型肝炎病毒（HCV）、登革病毒以及柯萨奇病毒、鼻病毒和脊髓灰质炎病毒等肠病毒感染相关的感染。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防病毒感染。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗病毒性疾病和病理状况的药物，例如但不限于与人类免疫缺陷病毒1（HIV1）、人类免疫缺陷病毒2（HIV2）、丙型肝炎病毒（HCV）、登革病毒以及柯萨奇病毒、鼻病毒和脊髓灰质炎病毒相关的病毒感染。
• [EN] PYRAZOLOPYRIMIDINES<br/>[FR] PYRAZOLOPYRIMIDINES
  申请人：PFIZER LTD

  公开号：WO2005049617A1

  公开（公告）日：2005-06-02

  This invention relates to compounds of formula (I).

  这项发明涉及到公式（I）的化合物。